The Functional and Metabolic Imaging Diagnostics Market is projected to register a strong CAGR during the forecast period (2026-2031).
The Functional and Metabolic Imaging Diagnostics Market is expanding as healthcare shifts toward advanced imaging techniques that visualize physiological and biochemical processes. Technologies such as PET, fMRI, and SPECT enable early disease detection and precision diagnostics. Rising chronic disease burden and demand for non-invasive imaging are driving growth.
Functional imaging refers to the ability to observe and evaluate various biological processes occurring in the body (e.g., metabolism, blood flow, cell activity) as opposed to simply assessing anatomical structure (e.g., size or shape). Some of the more commonly used forms of functional imaging technologies are positron emission tomography (PET), single-photon emission computerized tomography (SPECT), and functional magnetic resonance imaging (fMRI). Functional imaging is currently one of the fast-growing segments of medical imaging systems, particularly due to the increasing prevalence of neurological, cancer, and cardiovascular diseases. Using advanced imaging techniques and functional imaging systems will lead to the achievement of high levels of diagnostic accuracy compared to other (invasive) procedures. Functional imaging systems are making rapid advancements thanks to innovations in imaging biomarkers, artificial intelligence, and hybrid imaging systems. Research has shown that the functional imaging systems available today can accurately diagnose most conditions and allow real-time monitoring of patients.
Rising Prevalence of Chronic and Neurological Diseases: Chronic diseases like cancer, Alzheimer and Parkinson's are on the rise causing an increased demand for imaging methods that help diagnose those diseases early and accurately.
Advancements in Imaging Technologies: Image technology has been continuously innovated in PET scans, functional MRI and hybrid imaging systems, which can increase the amount of detail we can see with an image and create more accurate diagnoses and allows more places to begin using the technologies.
Growing Demand for Non-Invasive Diagnostics: Functional imaging provides a non-invasive way to view how we function physiologically and decreases the need for invasive procedures, and improves patient safety when obtaining information.
Expansion of Precision Medicine: Functional and metabolic imaging provides insight into a patient’s disease (how it happens, how fast it is growing, etc.) and improves the ability to personalise treatment based on how it will work with a specific patient and how it will help them recover after treatment.
Both the challenges that exist within the industry, as well as the opportunities available for growth are surfacing. Equipment cost, how to interpret images, and specialists required will continue to be challenged. However, there is potential for growth through AI-driven imaging, the development of new radiotracers, and expanding imaging biomarkers. Rapid adoption in research and clinical trials is also going to continue to create a sustainable growth environment in the years to come.
October 2025: In 2025, Siemens Healthineers advanced its molecular imaging portfolio with the introduction and clinical evaluation of the Biograph Vision.X PET/CT system, featuring faster time-of-flight (TOF) technology and improved sensitivity. This innovation enhances metabolic imaging accuracy, enabling better detection of subtle disease activity and supporting precision diagnostics in oncology and cardiology.
The market is segmented by product type, technology, application and geography.
PET is among the most significant imaging modalities available today because it can demonstrate metabolic activity on a cellular level. PET can be conducted using radiotracers like FDG that assess abnormal biochemical processes that occur before any structural change has occurred. PET will be commonly utilised in 2025 for both oncology and neurology by providing clinicians with early detection of a wide variety of cancers and neurological disorders, and continuing to monitor their treatment throughout the course of therapy. When PET is combined with other imaging modalities such as CT and MRI, the anatomic correlations will be greatly enhanced.
The components that make functional and metabolic imaging possible are radiotracers and contrast agents. These substances are able to modulate chemical pathways and show clinicians areas where there are unexpected levels of biological activity within the human body. The technological advancements made in 2025 to radiotracers that specifically target patients will enhance precision for diseases, particularly in oncological and neurological disorders. The continual advancements being made to safety, precision of imaging and reliability of diagnostic information will lead to a dramatic increase in the demand for these products.
Neurology is one of the major applications of functional and metabolic imaging because it allows for detailed assessment of cerebral activity, perfusion, and biochemistry. The use of fMRI, PET, and SPECT has allowed for the diagnosis of many neurological conditions, such as Alzheimer’s disease, Parkinson’s disease and seizures, in a timely and accurate manner. These technologies will be utilised increasingly to support early diagnosis and monitoring of many neurological disorders and provide clinicians with the ability to provide individualised treatment plans based on patient outcomes.
North America will dominate the imaging market because of the increasing use of diagnostic imaging equipment including PET, SPECT, and fMRI along with advanced infrastructure to support them. Additionally, the availability of funding for research and precision medicine from large imaging companies will further propel growth in this market. The increasing number of individuals with chronic diseases and the need for early diagnosis will also contribute to growth through an increase in the number of tests conducted with the use of imaging.
South America is undergoing moderate growth due to improvements in healthcare infrastructure and improved access to high-tech diagnostic imaging equipment. As there is an increasing prevalence of chronic illnesses, there will be an increase in the demand for diagnostic imaging services; however, due to economic constraints, it is anticipated that many countries will continue to have a limited amount of funds to acquire advanced imaging technologies. Continued funding for diagnostic imaging will provide steady growth over the next several years.
Europe continues to grow steadily as a result of extensive and strong healthcare systems and government funding to support digital imaging. The ongoing efforts throughout Europe to focus on early neurological and oncology diagnostic imaging will also continue to drive growth in the market through the use of functional imaging technologies. In addition, collaborative research efforts and regulatory support for new products will also create more opportunities and develop greater levels of innovation within the European market.
MEA is experiencing emerging growth due to the increase in government funding for healthcare and the advancement of their diagnostic imaging infrastructure. Some Middle Eastern countries are advancing the use of high-tech diagnostic imaging systems while African countries are slowly moving in that direction. An increase in awareness of the impact of early detection of disease will create additional opportunities for future business growth for diagnostic imaging within the MEA region.
Asia-Pacific is the region with the highest growth in the diagnostic imaging market due to an increase in healthcare funding from governments and the growing prevalence of chronic illnesses. Countries such as China, India, and Japan are developing their diagnostic imaging infrastructure. The growing awareness of the need for early diagnosis through the use of state-of-the-art equipment will continue to support robust growth within the region.
Siemens Healthineers
GE HealthCare
Philips Healthcare
Canon Medical Systems
Bracco Imaging
Curium Pharma
Lantheus Holdings
Eckert & Ziegler
Bayer AG
Fujifilm Healthcare
Siemens Healthineers is a leading provider of molecular and functional imaging systems, including PET/CT, SPECT, and PET/MRI platforms. The company focuses on precision diagnostics and theranostics, integrating AI-driven workflows to enhance clinical decision-making. Its strong portfolio supports oncology, neurology, and cardiology applications globally.
GE HealthCare offers advanced functional imaging technologies such as PET/CT and SPECT/CT, along with radiopharmaceuticals. The company emphasises precision medicine and early disease detection, particularly in cardiology and oncology. Its innovations in molecular imaging help improve diagnostic accuracy and patient outcomes.
| Report Metric | Details |
|---|---|
| Forecast Unit | Billion |
| Growth Rate | Ask for a sample |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Product Type, Technology, Application, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|